(Circulation. 1997;96:76-81.)
© 1997 American Heart Association, Inc.
Articles |
First Chronic Platelet Glycoprotein IIb/IIIa Integrin Blockade
A Randomized, Placebo-Controlled Pilot Study of Xemilofiban in Unstable Angina With Percutaneous Coronary Interventions
From The Department of Cardiology, Cell Biology (K.K.-M.), and Biostatistics and Epidemiology (D.P.M.), The Cleveland Clinic Foundation, Cleveland, Ohio, and GD Searle & Co (R.J.A., D.M.B.), Skokie, Ill.
Correspondence to Conrad Simpfendorfer, MD, Department of Cardiology, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195.
Background Clinical studies have demonstrated the efficacy of intravenous administration of agents that block platelet glycoprotein IIb/IIIa receptors in the setting of percutaneous coronary revascularization. Although the optimal duration of treatment has not been determined, more prolonged receptor blockade has been associated with increased efficacy. Orally active glycoprotein IIb/IIIa receptor antagonists may be advantageous and required for chronic therapy.
Methods and Results Thirty patients with unstable angina who were undergoing percutaneous coronary interventions were randomized to placebo or Xemilofiban 35 mg orally before and 20 to 25 mg TID for 30 days after angioplasty. Bleeding events, platelet aggregation, and pharmacokinetic and hematologic parameters were assessed during hospitalization and at 2 and 4 weeks after drug initiation. Xemilofiban produced a rapid, sustained, marked inhibition of platelet aggregation. ADP-induced platelet aggregation at 2 hours after the initial dose at 2 and 4 weeks was 15%, 8%, and 11% in the Xemilofiban group compared with 80%, 68%, and 69% in the placebo group. Among 20 patients randomized to Xemilofiban there was 1 death after emergency coronary bypass surgery complicated by severe bleeding diathesis, and 3 patients had major bleeding events. Patients on Xemilofiban for 30 days reported episodes of mild mucocutaneous bleeding.
Conclusions Xemilofiban, an orally active glycoprotein IIb/IIIa receptor inhibitor, produced rapid, sustained, extensive inhibition of platelet aggregation for a period of up to 30 days. At the dose initially tested, however, acute major bleeding and mucocutaneous bleeding during chronic administration were encountered.
Key Words: glycoproteins • platelets • angina • revascularization • drugs • platelet aggregation inhibitors
This article has been cited by other articles:
 |
|
 |
|
  S. Lehmann, T. Walther, J. Kempfert, S. Leontjev, A. Rastan, V. Falk, and F. W. Mohr Stentless Versus Conventional Xenograft Aortic Valve Replacement: Midterm Results of a Prospectively Randomized Trial Ann. Thorac. Surg., August 1, 2007; 84(2): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cohen, G. T. Christakis, C. D. Joyner, C. D. Morgan, M. Tamariz, N. Hanayama, H. Mallidi, J.P. Szalai, M. Katic, V. Rao, et al. Are stentless valves hemodynamically superior to stented valves? A prospective randomized trial Ann. Thorac. Surg., March 1, 2002; 73(3): 767 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. de Rossi, N. A. Horn, J. H. Baumert, K. Gutensohn, G. Hutschenreuter, and R. Rossaint Xenon Does Not Affect Human Platelet Function In Vitro Anesth. Analg., September 1, 2001; 93(3): 635 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119(1_suppl): 39S - 63S. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Curtin and D.J. Fitzgerald A cold start for oral glycoprotein IIb/IIIa antagonists Eur. Heart J., December 2, 2000; 21(24): 1992 - 1994. [PDF]
|
|
|
|
 |
|
 S. A. Mousa, J. M. Bozarth, M. S. Forsythe, and A. Slee Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels Cardiovasc Res, September 1, 2000; 47(4): 819 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Wong, M. E. Legget, S. C. Greaves, B. G. Barratt-Boyes, F. P. Milsom, and P. J. Raudkivi Early experience with the Mosaic bioprosthesis: a new generation porcine valve Ann. Thorac. Surg., June 1, 2000; 69(6): 1846 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mousa, S. Khurana, and M. S. Forsythe Comparative In Vitro Efficacy of Different Platelet Glycoprotein IIb/IIIa Antagonists on Platelet-Mediated Clot Strength Induced by Tissue Factor With Use of Thromboelastography : Differentiation Among Glycoprotein IIb/IIIa Antagonists Arterioscler. Thromb. Vasc. Biol., April 1, 2000; 20(4): 1162 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Verstraete Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa in Clinical Development Circulation, February 15, 2000; 101 (6): e76 - e80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Steinhubl, K. Kottke-Marchant, D. J. Moliterno, M. L. Rosenthal, N. K. Godfrey, B. S. Coller, E. J. Topol, and A. M. Lincoff Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention Circulation, November 9, 1999; 100(19): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mousa, R. Kapil, and D.-X. Mu Intravenous and Oral Antithrombotic Efficacy of the Novel Platelet GPIIb/IIIa Antagonist Roxifiban (DMP754) and Its Free Acid Form, XV459 Arterioscler. Thromb. Vasc. Biol., October 1, 1999; 19(10): 2535 - 2541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Quinn, A. Deering, M. Stewart, D. Cox, B. Foley, and D. Fitzgerald Quantifying GPIIb/IIIa Receptor Binding Using 2 Monoclonal Antibodies : Discriminating Abciximab and Small Molecular Weight Antagonists Circulation, May 4, 1999; 99(17): 2231 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kottke-Marchant, J. B. Powers, L. Brooks, S. Kundu, and D. J. Christie State-of-the-Art Review : The Effect of Antiplatelet Drugs, Heparin, and Preanalytical Variables on Platelet Function Detected by the Platelet Function Analyzer (PFA-100(R)) Clinical and Applied Thrombosis/Hemostasis, April 1, 1999; 5(2): 122 - 130. [Abstract] [PDF]
|
|
|
|
|
|
J. W. Smith, S. R. Steinhubl, A. M. Lincoff, J. C. Coleman, T. T. Lee, R. S. Hillman, and B. S. Coller Rapid Platelet-Function Assay : An Automated and Quantitative Cartridge-Based Method Circulation, February 9, 1999; 99(5): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Madan, S. D. Berkowitz, and J. E. Tcheng Glycoprotein IIb/IIIa Integrin Blockade Circulation, December 8, 1998; 98(23): 2629 - 2635. [Full Text] [PDF]
|
|
|
|
|
|
R.F. Storey, R.G. Wilcox, and S. Heptinstall Differential Effects of Glycoprotein IIb/IIIa Antagonists on Platelet Microaggregate and Macroaggregate Formation and Effect of Anticoagulant on Antagonist Potency : Implications for Assay Methodology and Comparison of Different Antagonists Circulation, October 20, 1998; 98(16): 1616 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Christakis, K. J. Buth, B. S. Goldman, S. E. Fremes, V. Rao, G. Cohen, M. A. Borger, and R. D. Weisel Inaccurate and misleading valve sizing: a proposed standard for valve size nomenclature Ann. Thorac. Surg., October 1, 1998; 66(4): 1198 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, N. S. Kleiman, J. J. Ferguson, A. R. Z. Masud, T. M. Broderick, C. W. Abbottsmith, J. P. Runyon, L. C. Anderson, R. J. Anders, R. J. Dreiling, et al. Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban : Results of a Multicenter, Placebo-Controlled, Randomized Trial Circulation, September 29, 1998; 98(13): 1268 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Mousa, J. M. Bozarth, W. Lorelli, M. S. Forsythe, M. J. M. C. Thoolen, A. M. Slee, T. M. Reilly, and P. A. Friedman Antiplatelet Efficacy of XV459, A Novel Nonpeptide Platelet GPIIb/IIIa Antagonist: Comparative Platelet Binding Profiles with c7E3 J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1277 - 1284. [Abstract] [Full Text]
|
|
|
|
|
|
D. A. Vorchheimer and V. Fuster Oral Platelet Glycoprotein IIb/IIIa Receptor Antagonists: The Present Challenge Is Safety Circulation, February 3, 1998; 97(4): 312 - 314. [Full Text] [PDF]
|
|
|
|
|
|
R. Altman Controversies in Antithrombotic Therapy in Cardiovascular Diseases Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24. [Abstract] [PDF]
|
|